These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 25994105)
1. The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer. Karachaliou N; Molina-Vila MA; Rosell R Expert Rev Respir Med; 2015 Jun; 9(3):241-4. PubMed ID: 25994105 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810 [TBL] [Abstract][Full Text] [Related]
4. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Yasuda H; Kobayashi S; Costa DB Lancet Oncol; 2012 Jan; 13(1):e23-31. PubMed ID: 21764376 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
6. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R; Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790 [TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039 [TBL] [Abstract][Full Text] [Related]
8. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. Murray S; Dahabreh IJ; Linardou H; Manoloukos M; Bafaloukos D; Kosmidis P J Thorac Oncol; 2008 Aug; 3(8):832-9. PubMed ID: 18670300 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer. Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844 [TBL] [Abstract][Full Text] [Related]
13. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
14. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686 [TBL] [Abstract][Full Text] [Related]